UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000012533 |
|---|---|
| Receipt number | R000014669 |
| Scientific Title | The effect of anagliptin on blood glucose and lipid levels in type 2 diabetes mellius |
| Date of disclosure of the study information | 2013/12/09 |
| Last modified on | 2017/06/13 10:22:23 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The effect of anagliptin on blood glucose and lipid levels in type 2 diabetes mellius
Acronym
The hypoglycemic and lipidemic effect of anagliptin in type 2 diabetes mellius
Scientific Title
The effect of anagliptin on blood glucose and lipid levels in type 2 diabetes mellius
Scientific Title:Acronym
The hypoglycemic and lipidemic effect of anagliptin in type 2 diabetes mellius
Region
| Japan |
Condition
Condition
Type 2 diabetes mellitus
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this study is to investigate the effect of anagliptin on glycemic control and safty in patients with type 2 diabetes.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Assessment
Primary outcomes
Change of HbA1c and lipid levels
Key secondary outcomes
1) Achiemement rate of blood glucose <130mg/dl
2) The change of glycemic and lipid parameters.
3)The analysis of backgorund factors which affect glycemic and lipid control
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 85 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1)before test registration -anagliptin within 2 weeks outpatient
2)Type 2 diabetes
3)HbA1c :more than 7.0%, less than 9%
4)No plan to add other OHA
5)Age more than 20, less than 85
6)Patients with written IC
Key exclusion criteria
1)Allergy for vildagliptin, linagliptin, repaglinide and glimepiride
severe infection, before operation, severe trauma
2)severe ketosis, diabetic coma within 6 months
3)severe hepatic dysfunction or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30)
4)pregnacy
5)Patients judged by the investigator to be ineligible for some other reason
Target sample size
100
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tadashi Yamakawa |
Organization
Yokohama City University Medical Center
Division name
Department of Endocrinology and Diabetes
Zip code
Address
4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
TEL
045-261-5656
naibunpi@urahp.yokohama-cu.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tadashi Yamakawa |
Organization
Yokohama City University Medical Center
Division name
Department of Endocrinology and Diabetes
Zip code
Address
4-57 Urafune-cho, Minami-ku, Yokohama City, 232-0024, Japan
TEL
045-261-5656
Homepage URL
naibunpi@urahp.yokohama-cu.ac.jp
Sponsor or person
Institute
Yokohama City University Medical Center
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
JAPAN
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 12 | Month | 09 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2013 | Year | 07 | Month | 11 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 12 | Month | 09 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
The purpose of this study is to investigate the effect of anagliptin on glycemic control and safty in patients with type 2 diabetes.
Management information
Registered date
| 2013 | Year | 12 | Month | 09 | Day |
Last modified on
| 2017 | Year | 06 | Month | 13 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014669
